GlassScriptPhysician profile
Jonathan I Segal
NPI 1902293210
$1,365.01
in general payments reported to CMS, 2019-2025
17 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $313 · 2023: $214 · 2024: $153 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $374.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $335.97 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $152.85 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.72 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $66.12 | 2022-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $50.50 | 2022-2023 | Opsumit |
| Esperion Therapeutics, INC. | $45.94 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.22 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $37.50 | 2022-2023 | Brilinta |
| Novo Nordisk INC | $34.48 | 2022 | |
| Tactile Systems Technology INC | $29.49 | 2023 | Flexitouch Plus, Entre Plus |
| Sanofi-Aventis U.S. LLC | $26.57 | 2023 | |
| Scpharmaceuticals INC. | $26.49 | 2025 | |
| Boston Scientific Corporation | $20.52 | 2025 | Watchman Access System |
| Merck Sharp & Dohme LLC | $20.15 | 2023 | Verquvo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.57 | 2023 | Repatha |
| Pfizer INC. | $15.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.